Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
New therapeutic targets for osteoporosis..
Maturitas. 120, 1-6.
(2019). Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis..
Endocrine. 62(2), 487-489.
(2018). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2018). Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis..
Expert Opin Drug Saf. 17(4), 413-428.
(2018). THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2018).
(2017).
Clinical vertebral fractures following denosumab discontinuation..
Endocrine. 54(1), 271-272.
(2016).
(2016). Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). Denosumab versus zoledronic acid in patients previously treated with zoledronic acid..
Osteoporos Int. 26(10), 2521-7.
(2015). Treatment of multiple myeloma bone disease: experimental and clinical data..
Expert Opin Biol Ther. 15(2), 213-30.
(2015). Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months..
Osteoporos Int. 25(5), 1633-42.
(2014). Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene)..
J Clin Endocrinol Metab. 99(3), 703-7.
(2014). Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial..
J Clin Endocrinol Metab. 98(8), 3206-12.
(2013). Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis..
Clin Endocrinol (Oxf). 79(4), 499-503.
(2013). Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis..
Med Hypotheses. 77(1), 109-11.
(2011). RANKL inhibition for the management of patients with benign metabolic bone disorders..
Expert Opin Investig Drugs. 18(8), 1085-102.
(2009).